Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

1.1%

1 terminated out of 90 trials

Success Rate

85.7%

-0.9% vs benchmark

Late-Stage Pipeline

4%

4 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed with results

Key Signals

2 with results86% success

Data Visualizations

Phase Distribution

66Total
Not Applicable (14)
Early P 1 (12)
P 1 (28)
P 2 (8)
P 3 (2)
P 4 (2)

Trial Status

Recruiting47
Not Yet Recruiting26
Completed6
Enrolling By Invitation4
Suspended2
Active Not Recruiting2

Trial Success Rate

85.7%

Benchmark: 86.6%

Based on 6 completed trials

Clinical Trials (90)

Showing 20 of 20 trials
NCT07854483Phase 1Not Yet RecruitingPrimary

A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)

NCT07840430Not ApplicableNot Yet RecruitingPrimary

Home-based Exercise for Improving Health-related Quality of Life in Systemic Sclerosis

NCT07839221Not Yet Recruiting

Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis

NCT06655155Phase 2RecruitingPrimary

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT07837986Not ApplicableNot Yet Recruiting

Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies

NCT06821659Phase 1Not Yet Recruiting

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

NCT07301164Early Phase 1Recruiting

Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

NCT06828042Phase 1Recruiting

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

NCT07732309Phase 1Not Yet Recruiting

A Study of ATG-201 in Adult Participants With Autoimmune Diseases

NCT06792344Phase 1SuspendedPrimary

Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

NCT07641634Phase 1Recruiting

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

NCT07806045Early Phase 1Not Yet Recruiting

Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement

NCT07800871Phase 1Recruiting

FT839 in Autoimmune Diseases

NCT07544225Phase 1Not Yet Recruiting

Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

NCT07188285Enrolling By Invitation

Mass Spectrometry-based Immune Profiling in Autoimmune Diseases

NCT07473154Phase 1Recruiting

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT07759557Phase 3Not Yet RecruitingPrimary

Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon

NCT06894654RecruitingPrimary

DERMATOMICS: Identifying Regulators of Skin Homeostasis

NCT06646913Not ApplicableCompleted

TENS in Scleroderma

NCT07523282Phase 1Not Yet Recruiting

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

Scroll to load more

Research Network

Activity Timeline